Uexküll & Stolberg – Germany 2021
This pure patent attorney firm is well positioned for proceedings at the EPO and in national nullity suits. Notable clients from the pharma, biotech and chemicals sectors have longstanding, solid relationships with Uexküll & Stolberg. Most recently, litigation for Amgen and BMS in high-stakes proceedings stood out. The team also made strides in litigation for biotech company Ohly.
Due to its strong focus on the life sciences sector and its broad client base overall, coronavirus-related restructuring in some companies has hardly affected the firm. Other clients invested in their portfolios or restructured them during the crisis. The solid prosecution work thus made steady progress. The long-established Hamburg firm is continuously investing in developing new talent.
Patent litigation with a technical focus on pharmaceuticals, biotech and chemicals.
Albrecht von Menges (“top for biotech”, competitor), Peter Franck, Ulrich-Maria Gross, Heinz-Peter Muth (“very well prepared”, competitor; all patent attorneys)
15 patent attorneys
All-round IP practice focusing on patent prosecution with broad technical expertise. Opposition and nullity suits. Infringement proceedings with external litigators. Also trademarks and unfair competition.
Litigation: Amgen (defendant) against Teva, Accord, Glenmark and Biogaran over cancer drug cinacalcet (public knowledge); Amgen (defendant) against Regeneron/Sanofi over antibodies; BMS (defendant) against Teva, Stada, Galenicum Generics over blood anticoagulant apixaban; Medac (defendant) against Eli Lilly over cancer drug pemetrexed; Ivoclar (defendant) against Vita Zahnfabrik over lithium silicate glass ceramic; Big Ben (claimant) against Nintendo over consumer electronics. Prosecution: filing and oppositions for ABB, Bayer/Monsanto, BMS, W. R. Grace, Chr. Hansen, Ivoclar, KRKA, Ohly; filing for Exxon, Helmholtz-Zentrum Geesthacht Centre for Materials and Coastal Research, Poly-Med, H&T Kongsberg Automotive, Marsberg, Presspart, Sealed Air (all public knowledge).